普瑞巴林胶囊致急性肝损伤1例分析

doi:10.19803/j.1672-8629.20250614

摘要/Abstract

摘要： 目的探讨普瑞巴林胶囊致急性肝损伤的特点,为临床安全用药和防治不良反应提供参考。方法分析1例口服普瑞巴林胶囊致急性肝损伤的病例,评价急性肝损伤与普瑞巴林的相关性,结合相关文献,对普瑞巴林致肝损伤机制进行分析,并提出防治建议。结果患者在用药12 d出现急性肝损伤,分析患者用药并查阅药品说明书及相关文献,考虑患者急性肝损伤与普瑞巴林相关。建议临床停药,患者在停药10 d并予保肝治疗后,肝功能指标基本恢复正常。结论临床治疗过程中应警惕普瑞巴林致肝损伤的风险,一旦出现肝损伤,及时停药,并给予对症处理,确保患者用药安全。

关键词: 普瑞巴林, 急性肝损伤, 药物性肝损伤, 药品不良反应, 合理用药

Abstract: Objective To explore the characteristics of acute hepatic injury caused by pregabalin capsules in order to provide a reference for safe clinical use and management of adverse reactions. Methods One case of acute hepatic injury caused by oral pregabalin capsules was analyzed. The correlations between hepatic injury and pregabalin were investigated, and the pathogenesis of acute hepatic injury caused by pregabalin was analyzed based on related literature before ways of prevention and treatment were recommended. Results The patient experienced hepatic injury after using pregabalin for 12 days. Clinical pharmacists traced the patient's medications, referred to the drug instructions and reviewed related literature before they concluded that hepatic injury was related to pregabalin. Therefore, they recommended that the drug be discontinued. The patient's liver function returned close to normal following hepatoprotective treatment ten days after discontinuation. Conclusion Clinicians are to be alert to the risk of such adverse reactions as hepatic injury caused by pregabalin. In case of hepatic injury, related drugs should be discontinued promptly and symptomatic treatment should be given to ensure safe medication.

Key words: Pregabalin, Acute Hepatic Injury, Drug-Induced Liver Injury, Adverse Drug Reactions, Rational Drug Use

中图分类号:

R971
R994.11

王阿明, 魏筱, 吴慧, 张琳琳, 杨莉. 普瑞巴林胶囊致急性肝损伤1例分析[J]. 中国药物警戒, 2026, 23(5): 578-580.

WANG Aming, WEI Xiao, WU Hui, ZHANG Linlin, YANG Li. One Case of Acute Hepatic Injury Caused by Pregabalin Capsules[J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 578-580.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250614

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I5/578

参考文献

[1] MAYORAL V, GALVEZ R, FERRÁNDIZ M, et al. Pregabalin vs Gabapentin in the Treatment of Neuropathic Pain:a Comprehensive Systematic Review and Meta-Analysis of Effectiveness and Safety[J]. Front Pain Res (Lausanne), 2025, 7(5):1513597.
[2] WANG XD, HUANG PW, FANG YL, et al.Assessment of off-Label Indications Use of Pregabalin by Evidence-Based Medicine Approach[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2024, 27(8):578-584.
[3] ZHU LX, LI J, XU ZH.Signal Mining and Analysis of Adverse Drug Event Signals of Pregabalin Based on Real World[J]. Drugs & Clinic(现代药物与临床), 2023, 38(6):1503-1508.
[4] CHEN Y, PENG J, LI C, et al.A Case of Acute Elevation of Hepatic Transaminases Caused by Pregabalin[J]. Chin J Hosp Pharm(中国医院药学杂志), 2023, 43(21):2467-2470.
[5] KOWAR M, FRIEDRICH C, JACOBS AH.Pregabalin as a Rare Cause of Liver Disease[J]. Dtsch Med Wochenschr, 2015, 140(23):1759-1760.
[6] MATSUMURA M, HIRANO T, KUBA H, et al.A Case of Acute Liver Failure Induced by Pregabalin and Celecoxib[J]. Kanzo, 2019, 60(9):323-331.
[7] WANG SS, XIAO L.Evaluation of the Rational Use of Pregabalin Based on the AHP-TOPSIS Method[J]. Drugs & Clinic(现代药物与临床), 2025, 40(6):1521-1527.
[8] CHEN JJ, QIAN PP, CAO K, et al.Comparison and Analysis of Causality Assessment Method in China and Naranjo’s Method in the Evaluation of Adverse Drug Reactions[J]. Chinese Pharmaceutical Affairs(中国药事) , 2020, 34(8):988-992.
[9] CRISWELL KA, COOK JC, MORSE D, et al.Pregabalin Induces Hepatic Hypoxia and Increases Endothelial Cell Proliferation in Mice, a Process Inhibited by Dietary Vitamin E Supplementation[J]. Toxicol Sci, 2012, 128(1):42-56.
[10] GHALEB SS, EID A, MICHEL ZAKI OG, et al.Toxicological Effects of Long Term Pregabalin Abuse on Liver of Adult Albinorats[J]. Minia J Med Res, 2021, 32(1):1-8.
[11] DÜZENLI T, ATA E, KÖSEM M, et al. Pregabalin as a Rare Cause of Hepatotoxicity[J]. Pain Med, 2017, 18(7):1407-1408.
[12] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association, Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese Guideline for Diagnosis and Management of Drug-Induced Liver Injury (2023 Version)[J]. Chin J Hepatol(中华肝脏病杂志), 2023, 31(4):355-382.
[13] GAO Y, SHI W, XIAO XH, et al.Research Progress on the Animal Models of Idiosyncratic Drug-Induced Liver Injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(1):33-39.
[14] PAN YZ, HU Y, LI QJ, et al.Research Progress on the Mechanism and Evaluation Methods of Idiosyncratic Drug-Induced Liver Injury[J]. Chin J Pharmacol Toxicol(中国药理学与毒理学杂志), 2020, 34(12):946-953.
[15] Chinese Medical Association Tuberculosis Branch. Guidelines for Diagnosis and Management of Drug Induced Liver Injury Caused by Anti Tuberculosis Drugs (2024 Version)[J]. Chin J Tuberc Respir Dis(中华结核和呼吸杂志), 2024, 47(11):1069-1090.
[16] HUANG L, LUO SP, TAN QH.Literature Analysis of 73 Cases of Adverse Drug Reactions by Pregabalin[J]. Anhui Medical and Pharma-ceutical Journal(安徽医药), 2019, 23(2):421-424.
[17] THOMPSON RR, KONG CL, PORCO TC, et al.Herpes Zoster and Postherpetic Neuralgia:Changing Incidence Rates from 1994 to 2018 in the United States[J]. Clin Infect Dis, 2021, 73(9):e3210-e3217.
[18] Chinese Association for the Study of Pain, Chinese Society of Derma-tology, Chinese Medical Doctor Association Pain Physician Branch, et al. Chinese Guideline for the Comprehensive Management of Zoster Associated Pain (2025 Version)[J]. Chinese Journal of Pain Medicine(中国疼痛医学杂志), 2025, 31(8):561-571.